Christine Fox - Mar 4, 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Head of U.S. Commercial
Signature
/s/ Dov Bergwerk as attorney-in-fact for Christine Fox
Stock symbol
TEVA
Transactions as of
Mar 4, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 04:35 PM
Previous filing
Nov 22, 2023
Next filing
Nov 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +81.8K $0.00 81.8K Mar 4, 2024 Ordinary Shares 81.8K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.